Revolutionary Products Available for First Time
"The creation of Catalyst represents the first time that many of these cutting edge technologies will be made available to industry," said Ian Ratcliffe, Stemgent's president and chief executive officer. "Dr. Ding's ground-breaking methods using proteins and small molecules to generate iPS cells and Dr. Jaenisch's innovative generation of a new way to model Parkinson's disease are just a few examples of the revolutionary products that will be made available - in commercial grade quality, reliability and scale - to Catalyst members."
Fate Therapeutics continues to be the leader in developing small molecules and biologics to modulate cell fate for regenerative medicine and therapeutic reprogramming indications, including hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. Stemgent accelerates the translation of stem cell science by providing application validated, proprietary reagents and tools developed by some of the world's leading stem cell scientists.
Commenting on Catalyst, Mr. Ratcliffe said, "Fate Therapeutics' stem cell biology expertise and Stemgent's superior reagent design and production capabilities make Catalyst an unmatched opportunity for the development of optimized small molecules and protein reagents for efficient and reproducible iPS cell generation and differentiation."
"Catalyst is the sole industry opportunity to access the most advanced iPS cell technology platform," said Paul Grayson, Fate Therapeutics' president and chief executive officer. "The Catalyst program represents a unique business collaboration amongst its participants to accelerate the translation of iPS cell technology into the discovery and development of safer and more effective therapeutics."
iPS cells are made by "reprogramming" fully differen
|SOURCE Fate Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved